Fortgeschrittenes Nierenzellkarzinom: Nivolumab plus Ipilimumab versus Sunitinib
- PMID: 30897630
- DOI: 10.1055/a-0603-7847
Fortgeschrittenes Nierenzellkarzinom: Nivolumab plus Ipilimumab versus Sunitinib
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
Comment on
-
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21. N Engl J Med. 2018. PMID: 29562145 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical